New Zealand’s Pharmac Mulls Amgevita Listing
Amgen’s Adalimumab Biosimilar Considered To Replace Humira As Principal Funded Brand
New Zealand’s Pharmac pharmaceutical management agency is considering funding Amgen’s Amgevita adalimumab biosimilar rather than the Humira reference brand from early 2022.
You may also be interested in...
A draft ICH guidance on continuous manufacturing has been opened up for comment by the FDA, as continuous manufacturing becomes an increasingly prominent topic for the generics industry.
Teligent is pursuing an asset sale process to “maximize the value of the company” after entering into Chapter 11 bankruptcy proceedings in the US. The firm – which has also seen CEO Tim Sawyer resign – had been struggling of late with remediation issues to address a warning letter at its Buena manufacturing facility in New Jersey, as well as a recent recall.
Looking back over a busy third quarter in 2021, Generics Bulletin executive editor David Wallace picks out highlights from July to September that include major legal and regulatory developments, multiple firsts in the biosimilars arena, significant M&A activity and our annual ranking of the off-patent sector’s top 50 companies.